Clinical Trials Logo

Clinical Trial Summary

Clinical study of Humira (adalimumab) or placebo in subjects with mild-moderate COVID-19


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04705844
Study type Interventional
Source Ology Bioservices
Contact
Status Withdrawn
Phase Phase 3
Start date September 2021
Completion date September 2022

See also
  Status Clinical Trial Phase
Recruiting NCT05941793 - A Study to Evaluate the Efficacy, Safety, and Concentration of SNS812 in Mild to Moderate COVID-19 Patients Phase 2
Terminated NCT04521296 - Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19 Compared to the Placebo Phase 2/Phase 3
Completed NCT05582629 - JT001 (VV116) for the Treatment of COVID-19 Phase 3
Completed NCT05620160 - Study of RAY1216 Tablets Compared With Placebo in Patients With Mild to Moderate COVID-19 Phase 3
Completed NCT06197217 - Phase III Clinical Study Evaluating the Efficacy and Safety of WPV01 in Patients With Mild/Moderate COVID-19 Phase 3
Recruiting NCT05675072 - Evaluate the Efficacy and Safety of FB2001 for Inhalation in Patients With Mild to Moderate COVID-19 Phase 2/Phase 3
Terminated NCT05242042 - JT001 (VV116) for the Early Treatment of COVID-19 Phase 2/Phase 3
Suspended NCT04711863 - Fluvoxamine for Adults With Mild to Moderate COVID-19 Phase 2